Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Limited Waiver under 18 U.S.C. §208(b)(3)

Curt	Furberg,	M.D	
------	----------	-----	--

Committees: Endocrinologic & Metabolic Drugs and the Drug Safety and Risk

Management Advisory Committees

Meeting Dates: July 30, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the discussions of the cardiovascular ischemic/thrombotic risks of the thiazolidinediones, with focus on rosiglitazone, as presented by the FDA and GlaxoSmithKline. I am eligible to receive a limited waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Data Safety Monitoring Board	NIH-sponsored study funded by the federal government, the sponsor, and 2 competing firms	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the limited waiver is not valid.

/s/	6/22/07
Signature of SGE	Date